ArticlePloS one2025
Circulating angiotensin-converting enzyme 2 concentration is associated with acute kidney injury and mortality in sepsis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mas receptor activation regulates the functional phenotype of myocardial macrophages through the Akt/Nrf2 signaling pathway to alleviate sepsis-induced cardiomyopathy.Journal of translational medicine · 2026Article
- Targeting the renin-angiotensin system in sepsis-associated AKI: from pathophysiology to precision medicine.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBeyond the well-established classical renin-angiotensin system (RAS), emerging evidence highlights the critical role of the non-classical RAS, specifically the Angiotensin (1-7)/ACE2/Mas axis. As the key enzyme converting Angiotensin II into Angiotensin (1-7), angiotensin-converting enzyme 2 (ACE2) exerts cardioprotective and anti-inflammatory effects, showing potential therapeutic value in critical care. This study investigates the association between circulating ACE2 levels and clinical outcomes in sepsis, offering insights into its role and potential for predicting sepsis outcomes. MATERIALS AND
methodsIn this single-center study, we investigated associations between the circulating ACE2 concentration and outcomes in septic patients admitted to a medical intensive care unit (ICU) between 01/05/2018 and 31/01/2021. Sepsis was defined as infection accompanied by a ≥2-point Sequential Organ Failure Assessment (SOFA) score increase. Patients were categorized into low (<2.5 ng/mL) and high (≥2.5 ng/mL) ACE2 groups based on serum concentrations within 24 hours of ICU admission. Outcomes comprised acute kidney injury (AKI), ICU mortality, and 90-day mortality.
resultsIn total, 414 patients (mean age 68.5 years, 64.7% male) were included in the study. Elevated ACE2 levels correlated positively with SOFA score and total bilirubin and lactate concentrations, and negatively with the hemoglobin concentration. Relative to the low ACE2 group, the high ACE2 group was at increased risk of sepsis-associated AKI development within 48 hours after ICU admission (81.6% vs. 69.6%, p = 0.006), AKI requiring renal replacement therapy (21.3% vs. 11.1%, p = 0.007), ICU mortality (31.9% vs. 17.5%, p = 0.001), and 90-day mortality (51.7% vs. 39.6%, p = 0.018). Kaplan-Meier survival curves demonstrated significantly reduced survival in individuals with high ACE2 concentrations (p = 0.009). Univariate analysis revealed significant associations of high ACE2 concentrations with ICU mortality and AKI development within 48 hours after ICU admission. In a multivariate analysis adjusted for relevant variables, ACE2 elevation remained an independent predictor of ICU mortality (adjusted odds ratio 2.15, 95% confidence interval 1.04-4.41, p = 0.038).
conclusionElevated circulating ACE2 concentrations comprised an independent predictor of ICU mortality, highlighting intricate RAS dynamics in critical illnesses. Low ACE2 concentrations were associated with greater survival, suggesting their potential as an early prognostic indicator.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.